



#5/7R
12/15/98

Express Mail No.: EM 061 017 954 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Murphy et al.

Serial No.: 09/016,737

Group Art Unit: To Be Assigned

Filed: January 30, 1998

Examiner: To Be Assigned

For: ISOLATION AND/OR
PRESERVATION OF DENDRITIC
CELLS FOR PROSTATE CANCER
IMMUNOTHERAPY

Attorney Docket No.: 8511-007

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA through DM listed on the attached revised form PTO 1449.

The above identified application is a continuation of PCT/US96/12389, filed July 29, 1996, which is a continuation-in-part of U.S. Patent Application Serial No. 08/509,254, filed July 31, 1995, now U.S. Patent No. 5,788,963. Pursuant to 37 C.F.R. §1.98(d), the Examiner is directed to the file of Application Serial No. 08/509,254 for copies of references (AA-DK). However, if the Examiner would prefer, a copy of each of the

identified references will be provided. A legible copy of each references (DL and DM) is provided herewith.


Identification of the above-listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited".

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, Applicants estimate that no fee is required. If a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150; a duplicate sheet of this is enclosed.

Respectfully submitted,

Date: December 1, 1998


Geraldine F. Baldwin 31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090